Enter keywords:  

Track companies' patents here: Public Companies RSS Feeds | RSS Feed Home Page
Popular terms


G Protein topics
Nucleic Acid
G Proteins
Nucleic Acids
Amino Acid
Protein A Affinity Chromatography
Liver Metastasis
Membrane Protein
Colorectal Carcinoma
Rectal Carcinoma

Follow us on Twitter
twitter icon@FreshPatents

Web & Computing
Cloud Computing
Search patents
Smartphone patents
Social Media patents
Video patents
Website patents
Web Server
Android patents
Copyright patents
Database patents
Programming patents
Wearable Computing
Webcam patents

Web Companies
Apple patents
Google patents
Adobe patents
Ebay patents
Oracle patents
Yahoo patents


G Protein patents

This page is updated frequently with new G Protein-related patent applications. Subscribe to the G Protein RSS feed to automatically get the update: related G RSS feeds. RSS updates for this page: G Protein RSS RSS

Date/App# patent app List of recent G Protein-related patents
 Cho-gmt recombinant protein expression patent thumbnailnew patent Cho-gmt recombinant protein expression
The present invention provides modified cells for producing proteins with modified glycosylation patterns. Proteins produced in such cells, and the use of such proteins in medicine, and particularly in the treatment of cancer, is also provided..
Agency For Science, Technology And Research
 Compounds useful for promoting protein degradation and methods using same patent thumbnailnew patent Compounds useful for promoting protein degradation and methods using same
The present invention includes compounds that act as degraders of a target protein, wherein degradation is independent of the class of the target protein or its localization. In certain embodiments, the invention comprises a compound comprising a protein degradation moiety covalently bound to a linker, wherein the clogp of the compound is equal to or higher than 1.5.
Yale University
 Mutant ros expression in human cancer patent thumbnailnew patent Mutant ros expression in human cancer
The invention provides the identification of the presence of mutant ros protein in human cancer. In some embodiments, the mutant ros are fig-ros fusion proteins comprising part of the fig protein fused to the kinase domain of the ros kinase.
Cell Signaling Technology, Inc.
 Methods of inhibiting adverse cardiac events and treating atherosclerosis and coronary artery disease using galectin-3 binding protein (gal-3bp, btbd17b, mac-2 binding protein) patent thumbnailnew patent Methods of inhibiting adverse cardiac events and treating atherosclerosis and coronary artery disease using galectin-3 binding protein (gal-3bp, btbd17b, mac-2 binding protein)
The invention provides galectin-3 binding protein (gal-3bp, btbd17b) polypeptide sequences and compositions that include gal-3bp polypeptide sequences, and methods of using gal-3bp polypeptide sequences, including modified forms and wild type (native) forms of gal-3bp polypeptide, such as in treatment, diagnostic, detection and prognostic methods.. .
La Jolla Institute For Allergy And Immunology
 Enzyme-based protein separation and enrichment from soy meal, wheat meal, and other protein-rich materials derived from plant seeds, fruits and other biomass patent thumbnailnew patent Enzyme-based protein separation and enrichment from soy meal, wheat meal, and other protein-rich materials derived from plant seeds, fruits and other biomass
The present invention is directed to enzyme based methods for separating protein from protein-rich materials derived from plant seeds, fruit, or other biomass and products made therefrom. The protein content in the resulting products is improved by separating and removing the carbohydrates from around the proteins in, for example, soybean meal.
The University Of Akron
 Method for reducing established metastatic tumor by pharmaceutical composition containing polypeptide patent thumbnailnew patent Method for reducing established metastatic tumor by pharmaceutical composition containing polypeptide
A method for reducing an established metastatic tumor, comprising administering an effective amount of a pharmaceutical composition to a subject in need, wherein the pharmaceutical composition comprises a polypeptide of a fibronectin-binding domain of dipeptidyl peptidase iv having a maltose-binding protein (mbp) fused at an n-terminal thereof, a cross-linking molecule, an active agent, and a pharmaceutically acceptable carrier.. .
National Cheng Kung University
 Delivery of negatively charged proteins using cationic lipids patent thumbnailnew patent Delivery of negatively charged proteins using cationic lipids
Compositions, methods, strategies, kits, and systems for the delivery of negatively charged proteins, protein complexes, and fusion proteins, using cationic polymers or lipids are provided. Delivery of proteins into cells can be effected in vivo, ex vivo, or in vitro.
President And Fellows Of Harvard College
 Method for treating glioma using tarbp2 patent thumbnailMethod for treating glioma using tarbp2
A pharmaceutical composition and a method for treating glioma are provided. The pharmaceutical composition for preventing or treating glioma includes a tar rna binding protein 2 (tarbp2) protein or gene encoding the same as an active component.
Research & Business Foundation Sungkyunkwan University
 Mutated fibroblast growth factor (fgf) 1 and methods of use patent thumbnailMutated fibroblast growth factor (fgf) 1 and methods of use
The present disclosure provides fgf1 mutant proteins, such as those having an n-terminal deletion, point mutation(s), or combinations thereof, which can reduce blood glucose in a mammal. Such mutant fgf1 proteins can be part of a chimeric protein that includes a β-klotho-binding protein, an fgfr1c-binding protein, a β-klotho-binding protein and a fgfr1c-binding protein, a c-terminal region from fgf19 or fgf21.
Salk Institute For Biological Studies
 Polymerized microarrays patent thumbnailPolymerized microarrays
Micropatterns of glycan-bearing brush polymers generated by the initiation of oligomerization of acrylate and methacrylate monomers from thiol-terminated surfaces. Chain lengths are controlled in situ by varying exposure time, and these multivalent glycan scaffolds detect glycan binding proteins at sub-micromolar concentrations..
New York University

Tnf-alpha binding proteins

Tnf-α binding proteins, including chimeric, cdr-grafted, and humanized antibodies that bind tnf-α are provided. Binding proteins have high affinity for tnf-α and neutralize tnf-α activity.
Abbvie Inc.

Recombinant bacterial host cell for protein expression

The present disclosure relates to a recombinant gram-negative bacterial cell comprising: a.) a mutant spr gene encoding a spr protein having a mutation at one or more amino acids selected from d133, h145, h157, n31, r62, i70, q73, c94, s95, v98, q99, r100, l108, y115, v135, l136, g140, r144 and g147 and b.) a gene capable of expressing or overexpressing one or more proteins capable of facilitating protein folding, such as fkpa, skp, sura, ppia and ppid, wherein the cell has reduced tsp protein activity compared to a wild-type cell, methods employing the cells, use of the cells in the expression of proteins in particular antibodies, such as anti fc rn antibodies and proteins made by the methods described herein.. .
Ucb Pharma S.a.

Method for peptide histochemical diagnosis

The present invention provides a method of peptide histochemical diagnosis to detect the peptide binding protein in the cancer tissue. This peptide binding specifically to tumor cells is linked to the dextran coated iron oxide nanoparticle.
National Taiwan University

Cell differentiation assay method, cell isolation method, producing induced pluripotent stem cells, and producing differentiated cells

Provided are a method for accurately evaluating the differentiation status of stem cells by selectively staining only stem cells in an undifferentiated state, and a method for positively isolating only stem cells in an undifferentiated state. Specifically provided is a method for determining differentiation of a cell comprising a step of contacting a test cell with a probe comprising protein (a) or (b) below and a step of detecting the presence of binding of the probe to the test cell.
Wako Pure Chemical Industries, Ltd.

Sterilized liquid protein supplement including a solubility enhancing nutritional protein

Disclosed are substantially stable sterilized liquid protein supplements including a highly soluble protein source for use with human milk and other infant or adult feeding formulas. The sterilized liquid protein supplements have a more neutral ph, thereby inhibiting protein denaturation and reducing microbial growth.
Abbott Laboratories

Multivalent meningococcal conjugates and methods for preparing conjugates

Disclosed herein are meningococcal immunogenic conjugates which can elicit immune responses against meningococcal polysaccharides (ps) from groups a, c, w-135, and y and group b factor h binding protein (fhbp). The disclosed conjugates also exhibit bactericidal activity against meningococcal a, c, w-135, y, b, and x serogroups.
Government Of The United States, As Represented By The Secretary Of The Army

Drug-conjugates with a targeting molecule and two different drugs

There is disclosed an improved adc (antibody drug conjugate) type composition having at least two different drug payloads conjugated to a single targeting protein. More specifically, the present disclosure attaches a first drug conjugate to a dual cysteine residue on a targeting protein and a second drug conjugate with a different drug to a lys residue on the targeting protein..
Sorrento Therapeutics Inc.

Methyl degron peptide and methods of controlling protein lifespan

The present invention provides an isolated methyl degron peptide and a fusion protein comprising a methyl degron peptide. Also, the present invention provides screening methods for agents affecting protein lifespan and anti-cancer agents.
Seoul National University (snu) R&d Foundation

Clinical diagnosis of hepatic fibrosis using a novel panel of low abundant human plasma protein biomarkers

The inventors have proposed a novel panel of human plasma protein biomarkers for diagnosing hepatic fibrosis and cirrhosis. Presently there is no reliable non-invasive way of assessing liver fibrosis.
The Chancellor, Masters And Scholars Of The University Of Oxford

Specific and high affinity binding proteins comprising modified sh3 domains of fyn kinase

The present invention relates to a method for the production of a library comprising recombinant derivatives of the sh3 domain of the fyn kinase of seq id no: 1 as well as a method for selecting from a library comprising recombinant derivatives of the sh3 domain of the fyn kinase of seq id no: 1 one or more of said derivatives having a specific binding affinity to a protein or peptide.. .
Eidgenoessische Technische Hochschule Zurich

Composition for diagnosing liver cancer and methods of diagnosing liver cancer and obtaining information for diagnosing liver cancer

Provided is method of diagnosing liver cancer in a subject, the method comprising contacting a sample from a subject with a substance that specifically binds to transmembrane emp24 domain trafficking protein 2 (tmed2), cluster of differentiation 43 (cd43), or any combination thereof on the surface of a microvesicle; and measuring the level of the substance bound to microvesicles in the sample; and related methods and compositions.. .
Samsung Electronics Co., Ltd.

Release reagent for vitamin d compounds

The present invention concerns a reagent composition for releasing vitamin d compounds bound to vitamin d-binding protein, a method for the detection of a 25-hydroxyvitamin d compound in which the 25-hydroxyvitamin d compound is released from vitamin d-binding protein using this reagent and the mixture obtained in this manner is analyzed, the use of the reagent to release vitamin d compounds as well as a kit for detecting 25-hydroxyvitamin d which contains the reagent for releasing vitamin d compounds in addition to the usual immunological reagents.. .
Roche Diagnostics Operations, Inc.

Protein manipulation

A method of improving the folding of an enzyme comprising a thiamine pyrophosphate (tpp) binding domain, the method comprising: providing a nucleic acid encoding the enzyme comprising a tpp binding domain, in which one or more of the tpp binding domains in the enzyme monomer are replaced with a tpp binding domain from a thermostable tpp-binding protein, and expressing the nucleic acid under conditions that allow expression and folding of the enzyme. The enzyme may be pyruvate decarboxylase..
Rebiotechnologies Limted

Method for pretreating biological sample containing protein

The present invention provides a method for pretreatment of a biological sample in the immunoassay of a protein contained in the biological sample. The method includes the steps of: (1) freezing the biological sample at a temperature higher than −80° c., in particular at −70° c.

Carriers for improved drug delivery

The invention provides carriers that enhance the absorption, half-life or bioavailability of therapeutic compounds. The carriers comprise targeting groups that bind the vitamin d binding protein (dbp), conjugation groups for coupling the targeting groups to the therapeutic compounds, and optionally scaffolding moieties..
Extend Biosciences, Inc.

Site-specific labeling methods and molecules produced thereby

The present disclosure provides methods of site-specific labeling of antibodies, using proteins having 4′-phosphopantetheinyl transferase activity that catalyze post-translational modification of peptide sequences (“peptide tags”) incorporated into one or more specific sites of an antibody of interest. Enzymatic labeling enables quantitative and irreversible covalent modification of a specific serine residue within the peptide tags incorporated into the antibody, and thus creates desirable antibody conjugates..
Irm Llc

Dual variable domain immunoglobulins and uses thereof

The present invention relates to engineered multivalent and multispecific binding proteins, methods of making, and specifically to their uses in the prevention, diagnosis, and/or treatment of disease.. .
Abbvie Inc.

Oligonucleotide compositions with enhanced efficiency

The oligonucleotide compositions of the present invention make use of combinations of oligonucleotides. In one aspect, the invention features an oligonucleotide composition including at least 2 different oligonucleotides targeted to a target gene.
Life Technologies Corporation

Insertion of charge in the hydrophobic interior of proteins as a strategy for engineering ph-sensitive switches

Methods are provided for engineering non-naturally occurring proteins comprising artificial ph-sensitive conformational switches that respond to a change in ph by causing a global unfolding of the proteins. Non-naturally occurring proteins comprising artificial ph-sensitive conformational switches that respond to a change in ph by causing a global unfolding of the proteins are also provided..
The Johns Hopkins University

Fluorescent proteins, split fluorescent proteins, and their uses

Disclosed herein are fluorescent proteins and split-fluorescent proteins (sfps) including split-green fluorescent proteins, such as tripartite split-gfps. Nucleic acid molecules encoding the fluorescent proteins and sfps, as well as methods of using the fluorescent proteins and sfps, are also disclosed.
Los Alamos National Security, Llc

Liquid formulations of tumor necrosis factor-binding proteins

The invention relates to a stable, pharmaceutically acceptable, aqueous formulation of tnf-binding protein, comprising a tnf-binding protein, a buffer and an isotonicity agent.. .
Ares Trading S.a.

Isolated egg protein and egg lipid materials, and methods for producing the same

A method for separating proteins and fats from an egg mixture is disclosed herein. The method includes a step of microfiltration of the egg mixture, wherein microfiltration includes pumping across a filter an egg mixture containing egg yolk and egg whites (albumen).
Rembrandt Enterprises, Inc.

Systems and methods for identifying protein stabilizers

A device for studying protein conformation transformation can include a macroscopic substrate, and chaperonin proteins bound to the substrate, each chaperonin protein being capable of binding to a protein of interest during or after undergoing protein conformation transformation. The device may also include the proteins of interest bound to the substrate, where the substrate is included in a label-free assay system.
The University Of Kansas

Method for determining the concentration of the adipocytic form of the fatty acid binding protein (a-fabp, fabp4, p2)

Products and methods for the research, diagnosis, risk assessment, course monitoring, treatment and prophylaxis of various metabolic disorders and their early forms, concomitant diseases and secondary diseases are provided. Metabolic diseases include, for example, metabolic syndrome, non-insulin-dependent diabetes, (type ii diabetes), insulin resistance, obesity (adiposis), in addition to diseases that are associated with disorders of the fatty acid metabolism.
Biovendor Laboratory Medicine, Inc.

Targeted and modular exosome loading system

Disclosed are exosomes that include a packaging protein and a cargo rna in which the packaging protein binds specifically to the cargo rna. The packaging protein is a fusion protein that includes an rna-binding domain and an exosome-targeting domain.
Northwestern University

Dual variable domain immunoglobulins and uses thereof

The present invention relates to engineered multivalent and multispecific binding proteins, methods of making, and specifically to their uses in the prevention, diagnosis, and/or treatment of disease.. .
Abbvie, Inc.

Goodpasture antigen binding protein detection and inhibition and its use in diabetes

Disclosed herein are methods for treating type 2 diabetes, limiting development of type 2 diabetes, and treating a pre-diabetic state by administering to a subject in need thereof a gpbp inhibitor. Also disclosed herein are methods for diagnosing a pre-diabetic state and for diagnosing a propensity to develop type 2 diabetes by determining an amount of gpbp in a sample from a subject and comparing to control..
Fibrostatin, S.l.

Human lambda light chain mice

Genetically modified mice are provided that express human λ variable (hvλ) sequences, including mice that express hvλ sequences from an endogenous mouse λ light chain locus, mice that express hvλ sequences from an endogenous mouse κ light chain locus, and mice that express hvλ sequences from a transgene or an episome wherein the hvλ sequence is linked to a mouse constant sequence. Mice are provided that are a source of somatically mutated human λ variable sequences useful for making antigen-binding proteins.
Regeneron Pharmaceuticals, Inc.

Using fluorescence measurements for characterizing protein gel-firming processes

The present invention relates to a method of predicting the cutting-time of coagulating milk based upon time parameters generated from fluorescence measurements. The method includes the steps of (a) measuring a change in the fluorescence response of coagulating milk, (b) generating time parameters from the fluorescence response, and (c) using time parameters and a cutting time prediction equation to predict cutting time.
Reflectronics, Inc.

Antigen binding proteins to proprotein convertase subtilisin kexin type 9 (pcsk9)

Antigen binding proteins that interact with proprotein convertase subtilisin kexin type 9 (pcsk9) are described. Methods of treating hypercholesterolemia and other disorders by administering a pharmaceutically effective amount of an antigen binding protein to pcsk9 are described.
Amgen Inc.

G protein-coupled purinergic receptor gpr17 mediates orexigenic effects of foxo1 in agrp neurons

g protein-coupled receptor (gpcr) gpr17 expressed in hypothalamic agouti-related peptide-expressing (agrp) neurons increases appetite and glucose tolerance and insulin sensitivity. By contrast, increasing gpr17 reduced glucose tolerance and increased appetite.
The Trustees Of Columbia University In The City Of New York

Affinity reagents for protein purification

Disclosed herein are methods and compositions for purifying proteins from crude solutions.. .
The Board Of Trustees Of The Leland Stanford Junior University

Compositions and methods for increasing the expression and signalling of proteins on cell surfaces

The present invention relates to the field of protein expression. More specifically, the present invention provides compositions and methods for increasing the expression and signaling of proteins on cell surfaces.
The Johns Hopkins University

Process for production of recombinant proteins as a soluble form

A target protein is prepared as soluble protein using a recombinant protein expression system. An expression vector is used that includes (1) an expression-inducible promoter sequence; (2) a first coding sequence including a polynucleotide coding for a polypeptide that is represented by the formula (z)n; and (3) a second coding sequence that includes a polynucleotide that codes for a target protein.
Jnc Corporation

Creamer composition comprising protein and hydroxypropyl starch

The present invention relates to a creamer composition, e.g. For use for addition into a coffee beverage, having good physical stability without the need for low molecular emulsifiers.
Nestec S.a.

Myostatin inhibition for enhancing muscle and/or improving muscle function

The present invention relates to methods for inhibiting myostatin, a regulator of muscle mass, for muscle enhancement (including inducing hypertrophy and/or hyperplasia) as well as improving muscle function (including decreasing atrophy and/or increasing endurance, force and/or strength). Some of the methods involve delivering genes to cells using gene delivery or other delivery techniques known in the art in order to inhibit myostatin.
Nationwide Children's Hospital

Alpha-4-beta-7 heterodimer specific antagonist antibody

There are disclosed alpha4beta7 heterodimer-specific antigen binding proteins, nucleic acids encoding them, and methods of making and using them.. .
Amgen Inc.

Anti-activin a antibodies and uses thereof

The disclosure provides compositions and methods relating to or derived from anti-activin a binding proteins, including antibodies. In particular embodiments, the disclosure provides fully human, humanized, and chimeric anti-activin a antibodies that bind human activin a, activin a-binding fragments and derivatives of such antibodies, and activin a-binding polypeptides comprising such fragments.
Amgen Inc.

Dual variable domain immunoglobulin and uses thereof

The present invention relates to engineered multivalent and multispecific binding proteins, methods of making, and specifically to their uses in the prevention and/or treatment of acute and chronic inflammatory and other diseases.. .
Abbvie Inc.

Chromatography matrices including novel staphylococcus aureus protein a based ligands

The present invention relates to chromatography matrices including ligands based on one or more domains of immunoglobulin-binding proteins such as, staphylococcus aureus protein a (spa), as well as methods of using the same.. .
Emd Millipore Corporation

Affinity chromatography matrix

The invention discloses an immunoglobulin-binding protein comprising one or more mutated immunoglobulin-binding domains (monomers) of staphylococcal protein a (e, d, a, b, c) or protein z or a functional variant thereof, wherein in at least one of the one or more mutated monomers, the asparagine or histidine at the position corresponding to h18 of the b domain of protein a or of protein z has been deleted or substituted with a first amino acid residue which is not proline or asparagine and wherein, if the amino acid residue at position 57 is proline and the amino acid residue at position 28 is asparagine, then the amino acid residue at the position corresponding to h18 of the b domain of protein a or of protein z is not serine, threonine or lysine.. .
Ge Healthcare Bio-sciences Ab

Substituted benzothienyl - pyrrolotriazines and uses thereof in the treatment cancer

This invention relates to novel substituted 5-(1-benzothiophen-2-yl)pyrrolo[2,1-fj[1,2,4]triazin-4-amine derivatives having protein tyrosine kinase inhibitory activities, to processes for the preparation of such compounds, to pharmaceutical compositions containing such compounds, and to the use of such compounds or compositions for treating proliferative disorders, in particular cancer and tumor diseases.. .
Bayer Pharma Aktiengesellschaft

Methods for isolating proteins

The invention generally relates to methods for isolating proteins. In certain aspects, methods of the invention involve preparing a plurality of sample preparations, each preparation including one or more intact cells.
Purdue Research Foundation

Popular terms: [SEARCH]

G Protein topics: Antibodies, Nucleic Acid, G Proteins, Nucleic Acids, Amino Acid, Polypeptide, Protein A Affinity Chromatography, Chromatography, Chromatograph, Liver Metastasis, Membrane Protein, Colorectal Carcinoma, Rectal Carcinoma, Prophylactic, Glycoprotein

Follow us on Twitter
twitter icon@FreshPatents


This listing is a sample listing of patent applications related to G Protein for is only meant as a recent sample of applications filed, not a comprehensive history. There may be associated servicemarks and trademarks related to these patents. Please check with patent attorney if you need further assistance or plan to use for business purposes. This patent data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for G Protein with additional patents listed. Browse our RSS directory or Search for other possible listings.



2 - 1 - 73